Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 6:3:158.
doi: 10.3389/fendo.2012.00158. eCollection 2012.

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

Affiliations

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

Meike Körner et al. Front Endocrinol (Lausanne). .

Abstract

Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are overexpressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtually all benign insulinomas highly overexpress GLP-1 receptors (GLP-1R). Targeting GLP-1R with the stable GLP-1 analogs (111)In-DOTA/DPTA-exendin-4 offers a new approach to successfully localize these small tumors. This non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. Malignant insulinomas, in contrast to their benign counterparts, express GLP-1R in only one-third of the cases, while they more often express the somatostatin type 2 receptors. Importantly, one of the two receptors appears to be always expressed in malignant insulinomas. The GLP-1R overexpression in selected cancers is worth to be kept in mind with regard to the increasing use of GLP-1 analogs for diabetes therapy. While the functional role of GLP-1R in neoplasia is not known yet, it may be safe to monitor patients undergoing GLP-1 therapy carefully.

Keywords: 111In-DOTA/DPTA-exendin-4; glucagon-like peptide-1; glucagon-like peptide-1 receptor; insulinoma.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Hormone and receptor determinations in vitro in a benign insulinoma. (A) Immunohistochemistry for insulin showing strongly labeled tumor cells. Bar = 0.01 mm. (B–D) In vitro GLP-1R autoradiography on consecutive insulinoma tissue sections. (B) Hematoxylin & eosin (H&E) staining showing the tumor tissue. Bar = 1 mm. (C) Autoradiogram showing total binding of 125I-GLP-1(7-36) amide. The entire tumor is strongly positive. (D) Autoradiogram showing non-specific binding of 125I-GLP-1(7-36) amide in the presence of 100 nM cold GLP1(7-36) amide. Reprinted from Christ et al. (2010), with permission from Elsevier.
FIGURE 2
FIGURE 2
111In-DOTA-exendin-4 whole-body planar images (A–C) and 111In-DOTA-exendin-4 SPECT/CT images (D,E) from the same patient. Whole-body scans were carried out 20 min (A), 4 h (B), and 3 days (C), and SPECT/CT scans were performed 4 h (D) and 3 days (E) after injection of 97 MBq 111In-DOTA-exendin-4. Four hours after injection, there was already a focal 111In-DOTA-exendin-4 uptake visible in the head of the pancreas (arrow) on whole-body (B) and SPECT/CT (D) scans. The tumor-to-pancreas-uptake ratio was 1.9 at 4 h after injection (D) and 3.2 at 3 days after injection of the radioligand. The longest residence times of 111In-DOTA-exendin-4 were observed in the tumor (arrow) and kidneys (C). Reprinted from Christ et al. (2009), with permission from The Endocrine Society.

References

    1. Baggio L. L., Drucker D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132 2131–2157 - PubMed
    1. Brom M., Oyen W. J., Joosten L., Gotthardt M., Boerman O. C. (2010). (68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur. J. Nucl. Med. Mol. Imaging 37 1345–1355 - PMC - PubMed
    1. Chatziioannou A., Kehagias D., Mourikis D., Antoniou A., Limouris G., Kaponis A., et al. (2001). Imaging and localization of pancreatic insulinomas. Clin. Imaging 25 275–283 - PubMed
    1. Christ E., Forrer F., Wild D., Clerici T., Braendle M., Maecke H., et al. (2012). Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients. Neuroendocrinology 96 24–24 - PubMed
    1. Christ E., Wild D., Forrer F., Brandle M., Sahli R., Clerici T., et al. (2009). Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 94 4398–4405 - PubMed